Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy
Science Advances · 23.05.2025 · 11 (21)
DOI: 10.1126/sciadv.adv6445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 23.05.2025. Verfasst von Yangyang Cai und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Bioinformatics Science and Technology, Harbin Medical University, H…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Antigens, Neoplasm, Precision Medicine. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Neoantigens have emerged as ideal targets for personalized cancer immunotherapy. We depict the pan-cancer peptide atlas by comprehensively collecting immunopeptidomics from 531 samples across 14 cancer and 29 normal tissues, and identify 389,165 canonical and 70,270 noncanonical peptides. We reveal that noncanonical peptides exhibit comparable presentation levels as canonical peptides across cancer types. Tumor-specific peptides exhibit significantly distinct biochemical characteristics compared with those observed in normal tissues. We further propose an immunopeptidomic-guided machine learning-based neoantigen screening pipeline (MaNeo) to prioritize neo-peptides as immunotherapy targets. Benchmark analysis reveals MaNeo results in the accurate identification of shared and tumor-specific canonical and noncanonical neo-peptides. Last, we use MaNeo to detect and validate three neo-peptides in cancer cell lines, which can effectively induce increased proliferation of active T cells and T cell responses to kill cancer cells but not damage healthy cells. The pan-cancer peptide atlas and proposed MaNeo pipeline hold great promise for the discovery of canonical and noncanonical neoantigens for cancer immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
- Department of Pharmacology (Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, PR China.
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), School of Interdisciplinary Medicine and Engineering, Harbin Medical University, Harbin, Heilongjiang 150081, China.
- The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
- Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, China.
ORCID-Profile: Yangyang Cai, Manyu Gong, Mengqian Zeng, Feng Leng, Jiyu Guo, Yapeng Li, Ying Zhang, Juan Xu, Yongsheng Li
Zitieren
APA
Cai, Y., Gong, M., Zeng, M., Leng, F., Lv, D., Guo, J., Wang, H., Li, Y., Lin, Q., Jing, J., Zhang, Y., Xu, J., & Li, Y. (2025). Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Science Advances, 11(21). https://doi.org/10.1126/sciadv.adv6445
Vancouver
Cai Y, Gong M, Zeng M, Leng F, Lv D, Guo J, et al. Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Science Advances. 2025;11(21). doi:10.1126/sciadv.adv6445
BibTeX
@article{Cai2025,
author = {Cai, Yangyang and Gong, Manyu and Zeng, Mengqian and Leng, Feng and Lv, Dezhong and Guo, Jiyu and Wang, Hao and Li, Yapeng and Lin, Quan and Jing, Jing and Zhang, Ying and Xu, Juan and Li, Yongsheng},
title = {Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {21},
doi = {10.1126/sciadv.adv6445}
}
EUVIMED